Protocol Ledger

NCT04609397 · Phase II · TERMINATED

A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease

Interventional Phase II clinical trial protocol NCT04609397 sponsored by Tianjin Hemay Pharmaceutical Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-11-30 Enrollment: 89 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04609397
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)89 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04609397
Protocol FieldVerified Registry Value
NCT IdentifierNCT04609397
Consolidated Lead SponsorTianjin Hemay Pharmaceutical Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment89 participants (ACTUAL)
Registered Start Date2020-11-30
WhyStopped ClassificationUnspecified

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI